Knowle House Surgery

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Obesity3 trials
• Type 2 diabetes3 trials
• High blood pressure2 trials
• Type 1 diabetes1 trial

Phase

• Phase 36 trials
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Mineralys Therapeutics Inc.2 trials
• Hoffmann-La Roche1 trial
• Novo Nordisk A/S1 trial

Running trials

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  NCT07339423· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

  NCT05433584· Phase 4· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source